Product
Miltefosine
Name
IMPAVIDO
INN Name
miltefosine
FDA Approved
Yes
6 clinical trials
1 organization
7 indications
1 document
Indication
LeishmaniasisIndication
Visceral LeishmaniasisIndication
Post-kala-azar Dermal LeishmaniasisIndication
Leishmaniasis; BrazilianIndication
MucocutaneousIndication
Cutaneous LeishmaniasisIndication
Mucosal LeishmaniasisClinical trial
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: An Open-label, Randomized Clinical Trial in BrazilStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern AfricaStatus: Completed, Estimated PCD: 2020-12-11
Clinical trial
Assessing Safety and Efficacy of Repurposed Oral Ivermectin in PKDL TreatmentStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the ElderlyStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Efficacy and Safety of Thermotherapy in Combination With Miltefosine Compared Iltefosine Monotherapy for the Treatment of New World Cutaneous Leishmaniasis: A Phase III, Open Label, Multicenter Randomized TrialStatus: Active (not recruiting), Estimated PCD: 2023-11-17
Clinical trial
Treatment of Bolivian Mucosal Leishmaniasis With Miltefosine, Pentavalent Antimony or Liposomal Amphotericin BStatus: Recruiting, Estimated PCD: 2024-04-30
Document
DailyMed Label: IMPAVIDOOrganization
Profounda, Inc.